Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.66 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.50 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.49 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8572804 | 0.95 | HDAC1 (0.63) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL16703059 | 0.88 | PLOD2 (0.61) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL8545882 | 0.85 | HDAC1 (0.68) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL7075878 | 0.84 | PLOD2 (0.69) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL9549825 | 0.83 | HDAC1 (0.70) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL3380708 | 0.83 | HDAC1 (0.70) | HDAC1HDAC8TBXAS1TBXA2RHDAC6 | |
| SCHEMBL7449419 | 0.83 | HDAC1 (0.66) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL552357 | 0.83 | HDAC1 (0.66) | HDAC1HDAC8PLOD2ALDH1A1TBXAS1 | |
| SCHEMBL9010434 | 0.83 | HDAC1 (0.66) | HDAC1HDAC8PLOD2ALDH1A1APP | |
| SCHEMBL30096366 | 0.83 | HDAC1 (0.65) | HDAC1HDAC8PLOD2ALDH1A1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703388-B2 | DIBENZODIAZEPINE DERIVATIVES; ANTIHISTAMINES, LEUKOTRIENE INHIBITORS, ANTIALLERGENS, ANTIASTHMATICS; HAY FEVER, ATOPIC DERMATITIS, AND URTICARIA TREATMENT | EISAI CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20030171367-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | EISAI CO., LTD. | 2003-09-11 | — | — | US | disclosed |
| US-6583138-B1 | Mediators or antagonists of the effects of histamine, leukotriene and the like; heterocyclic ring condensed benzothiazine compounds; inhibit the activation of the tyrosine kinase of 72 kDa | EISAI CO., LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| US-6489336-B2 | PHENOTHIAZINE, ACRIDAN, ACRIDONE OXIME, ACRIDONE HYDRAZONE, OR DIBENZODIAZEPINE DERIVATIVES; TYROSINE KINASE INHIBITORS; TREATING ALLERGIC DISEASES | EISAI CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020103189-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | EISAI CO., LTD. | 2002-08-01 | — | — | US | disclosed |
| US-6333322-B1 | FOR THERAPY OF ASTHMA, ALLERGIC RHINITIS, ATOPIC DERMATITIS, URTICARIA, HAY FEVER, GASTROINTESTINAL ALLERGY AND FOOD ALLERGY | EISAI CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-1057830-A1 | HETEROCYCLE-FUSED BENZOTHIAZINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0889037-A1 | NITROGENOUS TRICYCLIC COMPOUNDS AND DRUGS COMPRISING THE SAME | Eisai Co., Ltd. (JP) | 1999-01-07 | — | — | EP | disclosed |
| EP-0857721-A1 | ACRIDONE COMPOUNDS | Eisai Co., Ltd. (JP) | 1998-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171367-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | HRH2, HRH1, HRH4 | HDAC1 420/4885HDAC8 2746/4885PLOD2 1926/4885 |
| US-20020103189-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | HRH2, HRH1, HRH4 | HDAC1 420/4885HDAC8 2746/4885PLOD2 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.